A Phase 1b/2 Study of the BET inhibitor ZEN003694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations

被引：0

作者：

Aftimos, Philippe ^{[1
]}

Oliveira, Mafalda ^{[2
]}

Punie, Kevin ^{[3
]}

Boni, Valentina ^{[4
]}

Hamilton, Erika ^{[5
]}

Gucalp, Ayca ^{[6
]}

Shah, Payal ^{[7
]}

Mina, Lida ^{[8
]}

Sharma, Priyanka ^{[9
]}

Bauman, Lisa ^{[10
]}

Campeau, Eric ^{[11
]}

Attwell, Sarah ^{[11
]}

Snyder, Margo ^{[10
]}

Norek, Karen ^{[11
]}

Czibere, Akos ^{[12
]}

Yu, Yanke ^{[13
]}

Silverman, Michael H. ^{[10
]}

Lakhotia, Sanjay ^{[10
]}

Domchek, Susan ^{[7
]}

Litton, Jennifer ^{[14
]}

Robson, Mark ^{[6
]}

机构：

[1] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium

[2] Vall dHebron Inst Oncol, Barcelona, Spain

[3] UZ Leuven, Leuven, Belgium

[4] START, Madrid, Spain

[5] Sarah Cannon Res Inst, Nashville, TN USA

[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[7] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[8] Banner MD Anderson Canc Ctr, Gilbert, AZ USA

[9] Univ Kansas, Ctr Canc, Westwood, KS USA

[10] Zenith Epigenet, San Francisco, CA USA

[11] Zenith Epigenet, Calgary, AB, Canada

[12] Pfizer, Cambridge, MA USA

[13] Pfizer, La Jolla, CA USA

[14] Univ Texas MD Anderson, Houston, TX USA

来源：

CANCER RESEARCH | 2021年 / 81卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PS11-10

引用

页数：1

共 50 条

[41] Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasms
Tibes, Raoul
Kosiorek, Heidi E.
Dueck, Amylou C.
Palmer, Jeanne
Sproat, Lisa
Bogenberger, James
Hashmi, Shahrukh
Mesa, Ruben
Hogan, William
Litzow, Mark R.
Al-Kali, Aref
CANCER, 2023, 129 (15) : 2321 - 2330
[42] Association of anthracyclines induced cardiotoxicity (AIC) in patients with early breast cancer (eBC) with germline BRCA1/2 (gBRCA1/2) mutation: BRCAN study.
Serrano Domingo, Juan Jose
Cordero, David
Menacho, Miriam
Manuel del Rey, Jose
Chamorro, Jesus
Rosero, Diana I.
Sotoca, Pilar
del Campo, Laura
Alonso, Gonzalo
Saavedra Serrano, Cristina
Fernandez-Abad, Maria
Gion Cortes, Maria
Guerra, Eva M.
Martinez-Janez, Noelia
Lopez-Miranda, Elena
Vida Navas, Elena Maria
Fuentes Mateos, Raquel
Guillen Ponce, Carmen
Teresa Salazar, Maria
Cortes Salgado, Alfonso
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[43] Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study
Tolaney, Sara M.
Jhaveri, Komal
Helsten, Teresa
Puhalla, Shannon L.
Conlin, Alison
Dees, E. Claire
Beeram, Muralidhar
Chapman, Sonya C.
Lithio, Andrew
Litchfield, Lacey M.
Goetz, Matthew P.
FRONTIERS IN ONCOLOGY, 2025, 15
[44] Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia
Erba, Harry P.
Becker, Pamela S.
Shami, Paul J.
Grunwald, Michael R.
Flesher, Donna L.
Zhu, Min
Rasmussen, Erik
Henary, Haby A.
Anderson, Abraham A.
Wang, Eunice S.
BLOOD ADVANCES, 2019, 3 (13) : 1939 - 1949
[45] JAVELIN PARP Medley, a phase 1b/2 study of avelumab plus talazoparib: Results from advanced breast cancer cohorts
Yap, Timothy A.
Konstantinopoulos, Panagiotis
Telli, Melinda L.
Saraykar, Smita
Beck, J. Thaddeus
Galsky, Matthew D.
Abraham, Jame
Wise, David R.
Khasraw, Mustafa
Rubovszky, Gabor
Dvorkin, Mikhail
Joy, Anil A.
Opyrchal, Mateusz
Stypinski, Daria
Chappey, Colombe
Stewart, Ross
Cesari, Rossano
Scheuber, Anita
Bardia, Aditya
CANCER RESEARCH, 2020, 80 (04)
[46] Phase 1b/2a Study of ATR Inhibitor Tuvusertib + Anti-PD-1 Cemiplimab in Patients with Advanced NonSquamous NSCLC
Vokes, N.
Paz-Ares, L.
Cappuzzo, F.
Yamamoto, N.
Gray, J. E.
Owonikoko, T.
Ariyasu, R.
Ishii, H.
Kang, J. H.
Lee, S. -H.
Hallwachs, R.
Coenen-Stass, A.
Sarholz, B.
Pudelko, L.
Mukker, J. Kaur
Moulin, C.
Gounaris, I.
Villaruz, L. C.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S660 - S660
[47] CHRYSALIS-2: A phase 1/1b study of lazertinib as monotherapy and in combination with amivantamab in patients with EGFR-mutant NSCLC.
Shu, Catherine A.
Goto, Koichi
Cho, Byoung Chul
Griesinger, Frank
Yang, James Chih-Hsin
Felip, Enriqueta
Xie, John
Chen, Jun
Mahoney, Janine
Thayu, Meena
Knoblauch, Roland Elmar
Trani, Leonardo
Bauml, Joshua
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[48] Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma
Mar, Nataliya
Zakharia, Yousef
Falcon, Alejandro
Morales-Barrera, Rafael
Mellado, Begona
Duran, Ignacio
Oh, Do-Youn
Williamson, Stephen K.
Gajate, Pablo
Arkenau, Hendrik-Tobias
Jones, Robert J.
Teo, Min Yuen
Turan, Tolga
McLaughlin, Robert T.
Peltier, Hillary M.
Chong, Elizabeth
Atluri, Harisha
Dean, James P.
Castellano, Daniel
CANCERS, 2023, 15 (11)
[49] Impact of race on clinical outcomes among patients with advanced triple negative breast cancer (TNBC) and Germline BRCA1/2 mutation(s) (gBRCA1/2mut): Results from a US real-world study
Whitaker, Kristen
Parikh, Rohan
Esterberg, Elizabeth
Arondekar, Bhakti
Hitchens, Abigail
Arruda, Lillian Shahied
Niyazov, Alexander
Obeid, Elias
CANCER RESEARCH, 2022, 82 (04)
[50] A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Albiruni R. Abdul Razak
Hung-Ming Wang
Jang-Yang Chang
Myung-Ju Ahn
Pamela Munster
George Blumenschein
Benjamin Solomon
Darren Wan-Teck Lim
Ruey-Long Hong
David Pfister
Nabil F. Saba
Se-Hoon Lee
Carla van Herpen
Cornelia Quadt
Douglas Bootle
Lars Blumenstein
David Demanse
Jean-Pierre Delord
Targeted Oncology, 2023, 18 : 853 - 868

← 1 2 3 4 5 →